• Publications
  • Influence
The 1982 revised criteria for the classification of systemic lupus erythematosus.
The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification. TheExpand
  • 13,755
  • 467
  • PDF
Cyclophosphamide versus placebo in scleroderma lung disease.
BACKGROUND We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidenceExpand
  • 870
  • 35
  • PDF
Range of antinuclear antibodies in "healthy" individuals.
OBJECTIVE To determine the range of antinuclear antibodies (ANA) in "healthy" individuals compared with that in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc;Expand
  • 679
  • 20
Molecular cloning of cDNA for CENP-B, the major human centromere autoantigen
We have isolated a series of overlapping cDNA clones for approximately 95% of the mRNA that encodes CENP-B, the 80-kD human centromere autoantigen recognized by patients with anticentromereExpand
  • 358
  • 16
  • PDF
Lupus erythematosus: systemic and cutaneous manifestations.
Skin and joint involvements are the most commonly occurring manifestations of systemic lupus erythematosus. There are 3 forms of cutaneous lupus: chronic cutaneous (discoid) lupus, subacute cutaneousExpand
  • 121
  • 11
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
OBJECTIVE To document disease activity and functional status in patients with scleroderma (systemic sclerosis [SSc]) and Raynaud's phenomenon (RP) and to determine the sensitivity to change,Expand
  • 275
  • 8
  • PDF
Molecular cloning of a human homologue of Drosophila heterochromatin protein HP1 using anti-centromere autoantibodies with anti-chromo specificity.
We have identified a novel autoantibody specificity in scleroderma that we term anti-chromo. These antibodies recognize several chromosomal antigens with apparent molecular mass of between 23 and 25Expand
  • 168
  • 7
  • PDF
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
RATIONALE The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-relatedExpand
  • 359
  • 6
  • PDF
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
OBJECTIVE This study compares the responsiveness to change of the Medical Outcomes Study Short Form Health Survey (SF-36), a measure of health related quality of life (HRQOL), and the HealthExpand
  • 136
  • 6
cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment.
cDNA clones encoding human topoisomerase I were isolated from an expression vector library (lambda gt11) screened with autoimmune anti-topoisomerase I serum. One of these clones has been expressed asExpand
  • 231
  • 5